

Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer



Prospective External and Temporal Validation of the HAL and HOMER Models

Gabriela Martinez-Zayas, MD; Francisco A. Almeida, MD; Lonny Yarmus, DO; Daniel Steinfert, PhD; Donald R. Lazarus, MD; Michael J. Simoff, MD; Timothy Saettele, MD; Septimiu Murgu, MD; Tarek Dammad, MD; D. Kevin Duong, DO; Lakshmi Mudambi, MD; Joshua J. Filner, MD; Sofia Molina, MD; Carlos Aravena, MD; Jeffrey Thiboutot, MD; Asha Bonney, MD; Adriana M. Rueda, MD; Labib G. Debiane, MD; D. Kyle Hogarth, MD; Harmeet Bedi, MD; Mark Deffebach, MD; Ala-Eddin S. Sagar, MD; Joseph Cicenía, MD; Diana H. Yu, MD; Avi Cohen, MD; Laura Frye, MD; Horia B. Grosu, MD, MPH; Thomas Gildea, MD; David Feller-Kopman, MD; Roberto F. Casal, MD; Michael Machuzak, MD; Muhammad H. Arain, MBBS; Sonali Sethi, MD; George A. Eapen, MD; Louis Lam, MD; Carlos A. Jimenez, MD; Manuel Ribeiro, MD; Laila Z. Noor, MD; Atul Mehta, MD; Juhee Song, PhD; Humberto Choi, MD; Junsheng Ma, PhD; Liang Li, PhD; and David E. Ost, MD, MPH

BACKGROUND: Two models, the Help with the Assessment of Adenopathy in Lung cancer (HAL) and Help with Oncologic Mediastinal Evaluation for Radiation (HOMER), were recently developed to estimate the probability of nodal disease in patients with non-small cell lung cancer (NSCLC) as determined by endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA). The objective of this study was to prospectively externally validate both models at multiple centers.

RESEARCH QUESTION: Are the HAL and HOMER models valid across multiple centers?

STUDY DESIGN AND METHODS: This multicenter prospective observational cohort study enrolled consecutive patients with PET-CT clinical-radiographic stages T1-3, N0-3, M0 NSCLC undergoing EBUS-TBNA staging. HOMER was used to predict the probability of N0 vs N1 vs N2 or N3 (N2|3) disease, and HAL was used to predict the probability of N2|3 (vs N0 or N1) disease. Model discrimination was assessed using the area under the receiver operating characteristics curve (ROC-AUC), and calibration was assessed using the Brier score, calibration plots, and the Hosmer-Lemeshow test.

RESULTS: Thirteen centers enrolled 1,799 patients. HAL and HOMER demonstrated good discrimination: HAL ROC-AUC = 0.873 (95%CI, 0.856-0.891) and HOMER ROC-AUC = 0.837 (95%CI, 0.814-0.859) for predicting N1 disease or higher (N1|2|3) and 0.876 (95%CI, 0.855-0.897) for predicting N2|3 disease. Brier scores were 0.117 and 0.349, respectively. Calibration plots demonstrated good calibration for both models. For HAL, the difference

ABBREVIATIONS: CHEST = American College of Chest Physicians; EBUS-TBNA = endobronchial ultrasound-transbronchial needle aspiration; ESTS = European Society of Thoracic Surgery; HAL = acronym to the Help with the Assessment of Adenopathy in Lung cancer model; HOMER = acronym to the Help with Oncologic Mediastinal Evaluation for Radiation model; NCCN = National Comprehensive Cancer

Network; NSCLC = non-small cell lung cancer; ROC-AUC = area under the receiver operating characteristics curve; SABR = stereotactic ablative radiotherapy; SPN = solitary pulmonary nodule

AFFILIATIONS: From the Department of Pulmonary Medicine (G. Martinez-Zayas, S. Molina, H. B. Grosu, R. F. Casal, M. H. Arain, G. A.

between forecast and observed probability of N2|3 disease was +0.012; for HOMER, the difference for N1|2|3 was -0.018 and for N2|3 was +0.002. The Hosmer-Lemeshow test was significant for both models ($P = .034$ and $.002$), indicating a small but statistically significant calibration error.

INTERPRETATION: HAL and HOMER demonstrated good discrimination and calibration in multiple centers. Although calibration error was present, the magnitude of the error is small, such that the models are informative. CHEST 2021; 160(3):1108-1120

KEY WORDS: endobronchial ultrasound; lung cancer; lung cancer staging; mediastinal adenopathy

Correct mediastinal staging is critical for decision-making in non-small cell lung cancer (NSCLC) because treatment options and prognosis vary according to stage.¹ Surgical resection with mediastinal lymph node dissection is warranted for patients without nodal involvement (N0) and for select patients with ipsilateral

hilar nodal involvement (T1-2, N1).² For patients that cannot tolerate surgery because of comorbidities and those who refuse surgery, stereotactic ablative radiotherapy (SABR) may be an option, provided there is no mediastinal or hilar node involvement.³ Once mediastinal lymph nodes are involved, multimodality treatment with chemotherapy, radiation, or targeted therapy is usual.⁴

Eapen, C. A. Jimenez, L. Z. Noor, and D. E. Ost), The University of Texas MD Anderson Cancer Center, Houston, TX; the Department of Pulmonary Medicine (F. A. Almeida, J. Cicienya, T. Gildea, M. Machuzak, S. Sethi, L. Lam, M. Ribeira, A. Mehta, and H. Choi), Cleveland Clinic, Cleveland, OH; the Division of Pulmonary and Critical Care (L. Yarmus, J. Thiboutot, and D. Feller-Kopman), Johns Hopkins University, Baltimore, MD; the Department of Respiratory Medicine (D. Steinfurt and A. Bonney), Royal Melbourne Hospital, Melbourne, Australia; the Department of Medicine (D. Steinfurt), University of Melbourne, Melbourne, Australia; the Department of Pulmonary, Critical Care, and Sleep Medicine (D. R. Lazarus and A. M. Rueda), Baylor College of Medicine, Houston, TX; the Department of Pulmonary and Critical Care Medicine (M. J. Simoff, L. G. Debiante, and A. Cohen), Henry Ford Hospital, Detroit, MI; the Department of Pulmonary Disease and Critical Care Medicine (T. Saettele), Saint Luke's Hospital of Kansas City, Kansas City, MO; the Division of Pulmonary and Critical Care Medicine (S. Murgu and D. K. Hogarth), University of Chicago, Chicago, IL; the Department of Pulmonary Medicine (T. Dammad), University of New Mexico, Albuquerque, NM; the Department of Pulmonary and Critical Care Medicine (T. Dammad), CHRISTUS St. Vincent Medical Center, Santa Fe, NM; the Department of Pulmonary, Allergy and Critical Care Medicine (D. K. Duong and H. Bedi), Stanford University Medical Center and School of Medicine, Stanford, CA; the Division of Pulmonary and Critical Care (L. Mudambi and M. Deffebach), VA Portland Health Care System, Oregon Health and Science University, Portland, OR; the Department of Pulmonary Medicine (J. J. Filner), Northwest Permanente and The Center for Health Research, Kaiser Permanente Northwest, Portland, OR; the Department of Respiratory Diseases (C. Aravena), Pontificia Universidad Catolica de Chile, Santiago, Chile; the Department of Pulmonary Medicine (A.-E. S. Sagar), Banner MD Anderson Cancer Center, Gilbert, AZ; the Division of Pulmonary, Critical Care and Sleep Medicine (D. H. Yu), Keck School of Medicine, University of Southern California, Los Angeles, CA; the Division of Allergy, Pulmonary and Critical Care Medicine (L. Frye), University of Wisconsin, Madison, WI; and the Department of Biostatistics (J. Song, J. Ma, and L. Li), The University of Texas MD Anderson Cancer Center, Houston, TX.

FUNDING/SUPPORT: Statistical analysis work supported in part by the Cancer Center Support Grant (NCI Grant P30 CA016672).

CORRESPONDENCE TO: David E. Ost, MD, MPH; email: dost@mdanderson.org

Copyright © 2021 Published by Elsevier Inc under license from the American College of Chest Physicians.

DOI: <https://doi.org/10.1016/j.chest.2021.04.048>

Because lymph node involvement markedly impacts treatment decisions, the diagnostic approach to NSCLC revolves around assessment of the probability of lymph node involvement.⁵⁻⁷ Current American College of Chest Physicians (CHEST) and National Comprehensive Cancer Network (NCCN) guidelines suggest using PET-CT to look for evidence of lymph node metastasis.^{1,8} In patients with a sufficiently high probability of nodal metastasis, mediastinal lymph node sampling with a needle technique such as endobronchial ultrasound guided-transbronchial needle aspiration (EBUS-TBNA) is warranted.⁶ However, determining the probability of nodal disease is difficult because PET-CT, while useful, has limited sensitivity and specificity for nodal involvement.^{1,6}

The CHEST and NCCN guidelines have suggested using prediction models to estimate the probability of cancer to manage solitary pulmonary nodules (SPNs).^{6,8,9} Similarly, models exist to estimate the probability of nodal disease in patients with NSCLC, with varying success.¹⁰⁻¹⁷ Recently, the Help with the Assessment of Adenopathy in Lung cancer (HAL)¹⁰ and Help with Oncologic Mediastinal Evaluation for Radiation (HOMER)¹⁷ models were developed retrospectively and externally validated on three retrospective independent datasets. HAL is a binary logistic regression model, which predicts the probability of N0 or N1 disease (prN0|1) vs the probability of N2 or N3 disease (prN2|3) as determined by EBUS-TBNA.¹⁰ HOMER is an ordinal logistic regression model that predicts prN0 vs prN1

Take-home Points

Study Question: Are the HAL and HOMER models for predicting malignant mediastinal lymph node involvement valid across multiple centers?

Results: HAL and HOMER demonstrated good discrimination (ROC \geq 0.83) in 1,799 patients across 13 centers, and they demonstrated good calibration between forecast and observed probabilities of nodal disease (difference, +0.012 for HAL and -0.018 and +0.002 for HOMER).

Interpretation: In multiple centers, HAL and HOMER demonstrated good discrimination and calibration.

Study Design and Methods

This multicenter international prospective observational cohort study involved 13 different hospitals. All consecutive patients with untreated PET-CT clinical radiographic stage T1-3, N0-3, M0 NSCLC that underwent EBUS-TBNA staging were included. Patients who had CT-proven mediastinal invasion, distant metastases, synchronous primaries, recurrent disease, or small cell lung cancer were excluded (e-Table 1).^{10,17} The study was approved by the Institutional Review Board, Committee 4, Protocol PA16-0107 at the University of Texas MD Anderson on June 10, 2016, and enrollment closed on March 1, 2019 (e-Appendix 1).

All variable definitions were developed before data abstraction, provided to all sites, and are identical to previously published criteria for HAL and HOMER (see e-Appendix 1, Methods, for further details).^{10,17} PET-CT was used to define N stage and tumor location (central vs peripheral), using previously established definitions.^{10,17-19} Lymph node N stage was based on the radiology report and supplemented by interventional pulmonologist review. CT N stage was based on the enlargement of lymph nodes to \geq 1 cm on their short-axis diameter. PET N stage was based on the radiologist's assessment of fluorodeoxyglucose avidity in mediastinal and hilar lymph nodes. Radiographic N stage by PET and by CT were defined as the highest abnormal nodal station using The Eighth Edition Lung Cancer Stage Classification.²⁰ Central tumors were defined as those in the inner one third of the hemithorax (e-Fig 1).¹⁹

The predicted outcome variable was the presence of nodal involvement as determined by EBUS-TBNA. All EBUS-TBNA procedures used a systematic approach, defined as sampling of N3 nodes first, then N2 nodes, and finally N1 nodes.²¹ All lymph nodes \geq 0.5 cm by EBUS were sampled, independent of PET-CT status.²¹

Statistical Analysis

Prediction Models

HAL was used to calculate the predicted probability of the highest nodal station with malignant lymph node involvement for each patient. Highest nodal stage was determined by EBUS-TBNA and dichotomized as N0|1 vs N2|3 disease¹⁰ (Table 1).

HOMER was used to calculate the predicted probability of the highest nodal station with malignant lymph node involvement for each patient. Highest nodal stage was determined by EBUS-TBNA

vs prN2|3 as determined by EBUS-TBNA.¹⁷ HOMER performed well over long periods at the model development institution¹⁷ (ie, temporal validation), but performance over time was not measured at other hospitals. HAL has not been temporally validated at any site.

The objective of this study was to prospectively and externally validate HAL and HOMER at multiple new centers to determine whether these clinical prediction rules are suitable for generalized clinical use. The secondary objective was to temporally validate HAL (at the model development and external validation institutions) and HOMER (at the external validation institutions).

and was categorized in an ordinal fashion as N0 vs N1 vs N2|3.¹⁷ Because HOMER is an ordinal logistic regression model with three possible outcomes, two formulas constitute the model, one to predict the probability of N1 disease or higher (prN1|2|3) and another to predict prN2|3 (Table 1).

Temporal and External Validation

For HAL validation, prospective data from 13 hospitals (nine new plus original institutions) were used. For HOMER validation, prospective data from 12 hospitals (nine new plus original external validation institutions) were used, because the previously published temporal validation of HOMER used a portion of the model development institution data.¹⁷

Assessment of Model Performance

Model performance was assessed for discrimination using the area under the receiver operating characteristics (ROC) curve (AUC). Calibration was assessed using the Hosmer-Lemeshow goodness-of-fit test, Brier scores, and observed vs predicted graphs. We prespecified that the primary analysis would assess model performance for the entire cohort, and a secondary analysis would assess model performance stratified by institution.

Exploratory Analyses

Hospital-level variables have previously been shown to impact bronchoscopic diagnostic yield^{22,23} and might impact outcome and model performance. We used random effects models to test for center-level effects (e-Appendix 1).

In the previously published HAL and HOMER reports, model discrimination was good in all centers, but calibration was off in two centers.^{10,17} In those studies, institution-specific calibrated models were created (e-Table 2).^{10,17,24} We performed an exploratory analysis to temporally validate the calibrated models at their respective institutions (e-Appendix 1).

Sample Size

For the entire cohort, sample size was calculated so that the lower bound of the 95% CI for ROC-AUC would be 0.70 or higher. We chose the threshold value of 0.70 based on currently used clinical prediction models for SPNs (e-Table 3).²⁵ The rationale was that if the ROC-AUC lower limit of the 95% CI was 0.70 or greater and calibration was sufficient, then the model would potentially be clinically useful. Based on prior data and conservative assumptions, we estimated the ROC-AUC would be 0.73 and the prevalence of

TABLE 1] HAL and HOMER Prediction Formulas

Probability Being Predicted	HAL Model Formula
Predicted prN2 3 using HAL	$prN2 3 = \frac{\exp(A)}{1 + \exp(A)}$ where $A = -1.0663 - 0.0311 \times (\text{age of patient}) + 0.5881 \times I(\text{tumor location} = \text{central third of the lung}) - 0.8235 \times I(\text{tumor histology} = \text{squamous cell carcinoma}) + 0.1423 \times I(\text{Nonsmall cell lung carcinoma}) - 0.5079 \times I(\text{other primary lung cancer}) + 0.9694 \times I(\text{CT} = \text{N2 3, PET} = \text{N0}) + 1.5766 \times I(\text{CT} = \text{N0 N1, PET} = \text{N1}) + 0.9009 \times I(\text{CT} = \text{N2 N3, PET} = \text{N1}) + 2.3726 \times I(\text{CT} = \text{N0 1, PET} = \text{N2 3}) + 3.7531 \times I(\text{CT} = \text{N2 3, PET} = \text{N2 3})$
Probability being predicted	HOMER Model formula
Predicted prN1 2 3 using HOMER	$prN1 2 3 = \frac{\exp(B)}{1 + \exp(B)}$ where $B = -0.89 - 0.0292 \times (\text{age of the patient}) + 0.4864 \times I(\text{tumor location} = \text{central third of the lung}) - 0.8217 \times I(\text{tumor histology} = \text{squamous cell carcinoma}) + 0.0635 \times I(\text{tumor histology} = \text{nonsmall cell lung carcinoma}) - 0.4097 \times I(\text{tumor histology} = \text{other primary lung cancer}) + 1.1738 \times I(\text{CT} = \text{N2 3, PET} = \text{N0}) + 3.0832 \times I(\text{CT} = \text{N0 1, PET} = \text{N1}) + 2.9905 \times I(\text{CT} = \text{N2 3, PET} = \text{N1}) + 2.2595 \times I(\text{CT} = \text{N0 1, PET} = \text{N2 3}) + 3.7113 \times I(\text{CT} = \text{N2 3, PET} = \text{N2 3})$
Predicted prN2 3 using HOMER	$prN2 3 = \frac{\exp(C)}{1 + \exp(C)}$ where $C = -1.1576 - 0.0292 \times (\text{age of the patient}) + 0.4864 \times I(\text{tumor} = \text{centralof third the lung}) - 0.8217 \times I(\text{tumor histology} = \text{squamous cell carcinoma}) + 0.0635 \times I(\text{tumor histology} = \text{nonsmall cell lung carcinoma}) - 0.4097 \times I(\text{tumor histology} = \text{other primary lung cancer}) + 0.9798 \times I(\text{CT} = \text{N2 3, PET} = \text{N0}) + 1.5937 \times I(\text{CT} = \text{N0 1, PET} = \text{N1}) + 0.9323 \times I(\text{CT} = \text{N2 3, PET} = \text{N1}) + 2.3599 \times I(\text{CT} = \text{N0 1, PET} = \text{N2 3}) + 3.7486 \times I(\text{CT} = \text{N2 3, PET} = \text{N2 3})$
Predicted prN0 and prN1 derived from HOMER	Using HOMER, it follows that $prN0 = 1 - prN1 2 3$ and $prN1 = prN1 2 3 - prN2 3$.

I(X) is an indicator function and equals 1 if X is true, otherwise equals 0. exp(A) = exponential or base of the natural logarithm of A; exp(B) = exponential or base of the natural logarithm of B; exp(C) = exponential of base of the natural logarithm of C; prN0 = probability of N0 disease; prN1 = probability of N1 disease; prN1|2|3 = probability of N1 disease or higher; prN2|3 = probability of N2 or N3 disease.

N2|3 disease would be 23%, which resulted in a sample size of 1,252 patients (e-Appendix 1).²⁶ For the secondary analysis stratified by institution, we estimated that 100 patients per institution would provide precise calibration estimators and that 50 patients per institution would be sufficient to obtain a stable ROC-AUC for that center. Therefore, we prespecified that centers with fewer than 100 patients would be excluded from institution-level calibration assessment, and those with fewer than 50 patients would be excluded

from institution-level discrimination assessment, because estimates would be unreliable (see e-Appendix 1 for details). We therefore decided to enroll a minimum of 1,300 consecutive patients across 13 centers. Institutions were allowed to enroll more than 100 patients, but the goal was to have as many institutions reach the 100-patient threshold as possible.

All statistical analyses used SAS 9.4, STATA 15.1, and R 3.5.1.

Results

A total of 1,799 patients in 13 hospitals with clinical-radiographic T1-3, N0-3, M0 NSCLC as determined by PET-CT who underwent EBUS-TBNA were enrolled (Table 2).

Prospective External and Temporal Validation of HAL for Predicting N0|1 vs N2|3 Disease

Clinical characteristics according to nodal status (N0|1 vs N2|3) are shown in e-Table 4. Predictions using HAL demonstrated good discrimination and calibration in the validation cohort (n = 1,799). ROC-AUC was 0.873 (95% CI, 0.856-0.891; Fig 1A). Calibration as assessed by observed vs predicted plots (Fig 2A) and Brier score

(0.117) was good. However, the Hosmer-Lemeshow P value was significant (P = .034). The forecast vs observed prN2|3 disease was 0.251 and 0.239, respectively. Although the small Hosmer-Lemeshow P value suggests lack of calibration beyond random variation, the absolute magnitude of the calibration error is small (see Fig 2 and Brier scores) and may not be consequential from a clinical perspective; also, the impact of lack of calibration depends on the clinical context.²⁷

Three centers enrolled fewer than 50 patients per center (total n = 98). Excluding these patients from the combined analysis did not significantly impact discrimination (n = 1,701, ROC-AUC = 0.875; Fig

TABLE 2] Enrolled Patients Across 13 Different Hospitals

Variable	Overall (N = 2,127)	Excluded (n = 328)	Included (n = 1,799)
Institution, No. (%)			
Christus St. Vincent Santa Fe ^a	38 (1.8)	5 (1.7)	33 (1.8)
Cleveland Clinic Foundation	361 (17.0)	53 (13.0)	308 (17.6)
Henry Ford Hospital	112 (5.3)	4 (1.4)	108 (5.9)
Michael E. DeBakey Hospital	117 (5.5)	0 (0.0)	117 (6.4)
Johns Hopkins	239 (11.2)	46 (15.8)	193 (10.5)
Kaiser Permanente ^a	51 (2.4)	17 (5.8)	34 (1.9)
MD Anderson Cancer Center	679 (31.9)	124 (37.7)	555 (30.8)
Royal Melbourne Hospital	146 (6.9)	13 (4.5)	133 (7.2)
VA Portland Healthcare System	61 (2.9)	7 (1.4)	54 (3.1)
St. Luke's of Kansas City	103 (4.8)	1 (0.3)	102 (5.6)
Stanford University	67 (3.1)	3 (0.3)	64 (3.6)
University of Chicago	85 (4.0)	18 (5.8)	67 (3.7)
University of New Mexico ^a	68 (3.2)	37 (12.3)	31 (1.7)

^aInstitutions with fewer than 50 patients that were included for the combined cohort analysis but excluded from the stratified by institution analysis. The reasons of patients' exclusion are found in e-Table 1.

1B) or calibration (Brier score, 0.112; Hosmer-Lemeshow $P = .675$; forecast $prN2|3$ disease = 0.242, observed $prN2|3 = 0.220$). The Hosmer-Lemeshow P value is dependent on sample size. Therefore, an increase in P value with reduced sample size does not necessarily imply better calibration.²⁷

Model performance stratified by institution is provided in Table 3. Discrimination on a per-hospital basis remained good, with ROC-AUC ranging from 0.810 to 0.917 and Brier scores from 0.083 to 0.141.

Exploratory testing demonstrated presence of center-level effects. The random effects model using a random intercept is provided in e-Appendix 1. Although it did outperform the baseline HAL model ($P < .001$), the absolute magnitude of discrimination improvement was small (ROC-AUC improved from 0.873 to 0.887).

Details of the exploratory analysis comparing the previously published institution-specific calibrated models are summarized in e-Table 5. The baseline HAL model outperformed the institution-specific calibrated HAL models in every institution (e-Appendix 1).




Figure 1 – Receiver operating characteristic curves of the HAL model in the combined validation cohort. The figure plots the area under the curve (AUC) for A, N2 or N3 (vs N0 or N1) disease (AUC = 0.873) for all patients that met inclusion criteria from all 13 institutions (n = 1,799), and for B, N2 or N3 (vs N0 or N1) disease (AUC = 0.875) for patients that met inclusion criteria from institutions that had more than 50 eligible patients (n = 1,701). HAL = Help with the Assessment of Adenopathy in Lung cancer model.




Figure 2 – Observed vs predicted plots for the HAL model in the combined validation cohort for A, all patients that met inclusion criteria from all 13 institutions (n = 1,799) and B, for patients that met inclusion criteria from institutions that had more than 50 eligible patients (n = 1,701). The figure plots the probability of N2 or N3 (vs N0 or N1) disease by decile of expected risk as a function of the actual observed risk in that group. The observed probability for each decile is on the vertical axis; the predicted probability for each decile is on the horizontal axis. A perfect model, where observed = predicted, is shown by the line. HAL = Help with the Assessment of Adenopathy in Lung cancer model.

Prospective External and Temporal Validation of HOMER for Predicting N0 vs N1 vs N2|3 Disease

Clinical characteristics according to nodal status (N0 vs N1 vs N2|3) are shown in e-Table 6. Predictions using

HOMER demonstrated good discrimination and calibration in the validation cohort (n = 1,244). ROC-AUC was 0.837 (95% CI, 0.814-0.859; Fig 3A) for predicting prN1|2|3 (vs prN0) disease and 0.876

TABLE 3] HAL Model Performance at Different Institutions

Population	ROC-AUC (95% CI)	Brier Score	Observed prN2 3 (vs N0 1)	Forecast prN2 3 (vs N0 1)	Hosmer-Lemeshow P
Entire cohort (n = 1,799)	0.873 (0.856-0.891)	0.117	0.239	0.251	.034
Cohort excluding centers with <50 patients (n = 1,701)	0.875 (0.856-0.894)	0.112	0.220	0.242	.675
MD Anderson Cancer Center ^a (n = 555)	0.871 (0.835-0.949)	0.109	0.193	0.228	.0467
Cleveland Clinic Foundation ^b (n = 308)	0.913 (0.880-0.945)	0.092	0.182	0.216	.704
Henry Ford Hospital ^b (n = 108)	0.848 (0.772-0.924)	0.136	0.269	0.290	.293
Johns Hopkins ^b (n = 193)	0.838 (0.776-0.899)	0.141	0.285	0.304	.280
Royal Melbourne Hospital ^c (n = 133)	0.917 (0.862-0.973)	0.110	0.338	0.230	.010
Michael E. DeBakey VA Hospital ^c (n = 117)	0.912 (0.847-0.977)	0.083	0.188	0.165	.768
St. Luke's of Kansas City ^c (n = 102)	0.887 (0.813-0.962)	0.120	0.245	0.204	.459
VA Portland Healthcare System ^c (n = 54)	0.909 (0.828-0.990)	NA	NA	NA	NA
Stanford University ^c (n = 64)	0.839 (0.742-0.937)	NA	NA	NA	NA
University of Chicago ^c (n = 67)	0.810 (0.692-0.989)	NA	NA	NA	NA

Brier scores range from 0 (perfect) to 1 (worst) for a binary outcome. EBUS-TBNA = endobronchial ultrasound guided-transbronchial needle aspiration; NA = Not applicable because enrollment did not reach the required n ≥ 100 for these centers; N0|1 = N0 or N1; prN2|3 = probability of N2 or N3 disease; ROC-AUC = area under the receiver operator characteristic curve.

^aHospital where HAL was developed; data tests temporal validation.

^bHospital where HAL was previously tested; new data tests temporal external validation of HAL.

^cHospital where HAL was never tested before; external validation of HAL.




Figure 3 – Receiver operating characteristic curves of the HOMER model in the combined validation cohort. The figure plots the area under the curve (AUC) for A, N1 or higher (vs N0) disease (AUC = 0.837) and B, N2 or N3 (vs N0 or N1) disease (AUC = 0.876) for all patients that met inclusion criteria from all non-MDACC institutions ($n = 1,244$), and for C, N1 or higher (vs N0) disease (AUC = 0.837) and D, N2 or N3 (vs N0 or N1) disease (AUC = 0.878) for patients that met inclusion criteria from non-MDACC institutions that had more than 50 eligible patients ($n = 1,146$). HOMER = Help with Oncologic Mediastinal Evaluation for Radiation; MDACC = MD Anderson Cancer Center.

(95% CI, 0.855-0.897; Fig 3B) for predicting prN2|3 (vs prN0|1) disease. Calibration as assessed by observed vs predicted plots (Figs 4A, 4B) and Brier score (0.349) was good. However, the Hosmer-Lemeshow P value was significant ($P = .002$). The forecast vs observed prN1|2|3 disease was 0.339 and 0.357, respectively. The forecast vs observed prN2|3 disease was 0.261 and 0.259, respectively.

Excluding centers that enrolled fewer than 50 patients did not significantly change discrimination for prN1|2|3 ($n = 1,146$; ROC-AUC = 0.837; Fig 3C) and prN2|3 (ROC-AUC = 0.878, Fig 3D), or calibration (Brier score, 0.341; Hosmer-Lemeshow $P < .001$; observed vs predicted plots, Figs 4C and 4D, forecast prN1|2|3 vs observed prN1|2|3 was 0.325 and 0.335, respectively,

and forecast prN2|3 disease vs observed prN2|3 was 0.249 and 0.233, respectively).

Model performance stratified by institution demonstrated good discrimination in eight of nine hospitals, with ROC-AUC ranging from 0.711 to 0.912 (Table 4) for prN1|2|3 (vs N0) disease, and diminished discrimination in one hospital (ROC-AUC = 0.672; Table 4). Discrimination was good in all hospitals for prN2|3 (vs N0|1) disease, with ROC-AUC ranging from 0.809 to 0.919 (Table 4). Calibration on a per-hospital basis was similar, with Brier scores ranging from 0.283 to 0.370 (Table 4).

Exploratory testing using a random effects model demonstrated the presence of center-level effects (e-Appendix 1). Although the random effects model did




Figure 4 – Observed vs predicted plots for the HOMER model in the combined validation cohort. The figure plots the probability of N1 or higher (vs N0) disease for A and the probability (B) of N2 or N3 (vs N0 or N1) disease by decile of expected risk for all patients that met inclusion criteria from all non-MDACC institutions ($n = 1,244$) and the probability of (C) N1 or higher (vs N0) disease and the probability of (D) N2 or N3 (vs N0 or N1) disease by decile of expected risk for patients that met inclusion criteria from non-MDACC institutions that had more than 50 eligible patients ($n = 1,146$). The observed probability for each decile is on the vertical axis; the predicted probability for each decile is on the horizontal axis. A perfect model, where observed = predicted, is shown by the line. HOMER = Help with Oncologic Mediastinal Evaluation for Radiation; MDACC = MD Anderson Cancer Center.

outperform the baseline HOMER model ($P < .001$ for predicting prN1|2|3 [vs N0] disease and $P < .001$ for predicting prN2|3 [vs N0|1] disease), the absolute magnitude of discrimination improvement was small (ROC-AUC improved from 0.837 to 0.854 for predicting prN1|2|3 [vs N0] disease and from 0.876 to 0.891 for predicting prN2|3 [vs N0|1] disease).

Details of the exploratory analysis comparing the previously published institution-specific calibrated models are summarized in e-Table 7. The baseline HOMER model outperformed the institution-specific

calibrated HOMER models in every institution (e-Appendix 1).

Discussion

In this study, we prospectively and externally validated the HOMER and HAL models, which estimate the probability of metastatic nodal disease in NSCLC patients as determined by EBUS-TBNA. We found that both models performed well in multiple outside institutions. External validation confirmed good discrimination. Although the Hosmer-Lemeshow test

TABLE 4] HOMER Model Performance at Different Institutions

Population	ROC-AUC prN1 2 3 (95% CI)	ROC-AUC prN2 3 (95% CI)	Brier Score	Observed prN1 2 3 (vs N0)	Forecast prN1 2 3 (vs N0)	Observed prN2 3 (vs N0 1)	Forecast prN2 3 (vs N0 1)	HL <i>P</i>
Entire non-MDACC cohort (n = 1,244)	0.837 (0.814-0.859)	0.876 (0.855-0.897)	0.349	0.357	0.339	0.259	0.261	.002
Non-MDACC data excluding centers with <50 patients (n = 1,146)	0.837 (0.813-0.860)	0.878 (0.86-0.900)	0.341	0.335	0.325	0.233	0.249	<.001
Cleveland Clinic Foundation ^a (n = 308)	0.851 (0.803-0.912)	0.912 (0.879-0.945)	0.283	0.263	0.290	0.182	0.218	.098
Henry Ford Hospital ^a (n = 108)	0.812 (0.729-0.897)	0.849 (0.773-0.924)	0.345	0.389	0.361	0.269	0.289	.008
Johns Hopkins ^a (n = 193)	0.803 (0.739-0.867)	0.838 (0.777-0.900)	0.363	0.363	0.380	0.285	0.302	.038
Royal Melbourne Hospital ^b (n = 133)	0.878 (0.819-0.938)	0.919 (0.864-0.974)	0.370	0.504	0.402	0.338	0.288	.027
Michael E. DeBakey VA ^b (n = 117)	0.912 (0.857-0.966)	0.911 (0.845-0.978)	0.263	0.265	0.208	0.188	0.169	.148
St. Luke's of Kansas City ^b (n = 102)	0.867 (0.798-0.937)	0.887 (0.813-0.962)	0.332	0.333	0.276	0.245	0.205	.354
VA Portland ^b (n = 54)	0.886 (0.786-0.985)	0.911 (0.832-0.990)	NA	NA	NA	NA	NA	NA
Stanford University ^b (n = 64)	0.711 (0.581-0.841)	0.834 (0.736-0.932)	NA	NA	NA	NA	NA	NA
University of Chicago ^b (n = 67)	0.672 (0.535-0.809)	0.809 (0.691-0.927)	NA	NA	NA	NA	NA	NA

Brier scores range from 0 (perfect) to 2 (worst) when there are three possible outcomes, so the interpretation is different for HOMER and HAL. The lower Brier scores in HAL do not imply the HAL is better than HOMER. H-L = Hosmer-Lemeshow; MDACC = MD Anderson Cancer Center; N0|1 = N0 or N1; NA = not applicable because enrollment did not reach the required $n \geq 100$ for these centers; prN1|2|3 = probability of N1 disease or higher; prN2|3 = probability of N2 or N3 disease; ROC-AUC = area under the receiver operator characteristic curve.

^aHospital where HOMER was previously validated, new data here tests temporal external validation of HOMER.

^bHospital where HOMER was never tested before, external validation of HOMER.

suggested some calibration error beyond random variation, the calibration error was small and not evident as assessed by observed vs predicted plots and Brier scores.²⁷ The forecast vs observed probabilities of disease for HAL (25.1% vs 23.9% for N2|3) and HOMER (33.9% vs 35.7% for N1|2|3 and 26.1% vs 25.9% for N2|3) suggest that HAL slightly overestimates the prN2|3 disease, whereas HOMER overestimates the prN0 disease.

Graphically this means that the curve in the observed vs predicted plots for HAL (Fig 2) is slightly but statistically significantly shifted to the right of the perfect prediction line. For HOMER, in the plot of prN1|2|3 (vs N0) disease (Fig 4A), the curve is shifted slightly to the left. This shift is a representation of the Hosmer-Lemeshow goodness-of-fit test, which tests overall calibration error. However, the absolute magnitude of the shift is small, as reflected in the difference between forecast and observed probabilities (+1.2% difference for HAL and -1.8% and +0.2% for HOMER for prN1|2|3 and prN2|3, respectively). Therefore, the data suggest that although calibration error is present, the magnitude of the difference is relatively modest, such that the models are informative.²⁷

How well clinical prediction models perform over extended periods is important if they are to be used in everyday practice. The original HAL model¹⁰ used data from 2009, and the last patients in this study were from 2019. Both HAL and HOMER demonstrate good discrimination and calibration over a 10-year period at the four centers that performed both studies, providing evidence of temporal validation and stability over time.

Improving decision-making during the evaluation of lung cancer is fundamental to improve the value of patient care.²⁸ ACCP and NCCN guidelines suggest that mediastinal lymph node sampling with EBUS be performed as the first invasive test in patients with sufficiently high probability of nodal disease. Inaccurate estimates of the probability of nodal disease can in turn lead to ineffective staging. For example, examination of SEER-Medicare data from 2004 to 2013 shows that only 23% to 34% of patients with lung cancer stage T1-3, N1-3, M0 disease received mediastinal sampling as part of their first invasive test, as recommended by guidelines.²⁹ Instead of guideline-consistent care, most patients had a biopsy of the peripheral nodule or mass first, usually using a percutaneous CT-guided approach. Mediastinal

sampling was delayed and sometimes never done. Unfortunately, this guideline-inconsistent pattern of care led to more biopsies and more complications. One factor contributing to this quality gap in cancer care is the difficulty in quantifying the probability of mediastinal and hilar nodal involvement.

Clinical prediction rules such as HAL and HOMER can help address this problem by better informing providers as to the probability of nodal involvement. HAL and HOMER demonstrated adequate discrimination and fairly good calibration. We believe that on balance HAL and HOMER remain informative and can improve decision-making during the evaluation of lung cancer analogous to the VA and Mayo models for SPNs.

HAL and HOMER can also inform decisions in scenarios in which the guidelines' recommendations for the next step in management is not clear, such as determining whether a PET-scan is required after CT staging when EBUS is being considered, whether performing EBUS-TBNA is warranted after PET-CT imaging is done, and whether confirmatory mediastinoscopy after a negative EBUS-TBNA is required.^{1,2,4,8,10,17} For example, consider a 60-year-old patient with a peripherally located, CT N0 stage adenocarcinoma. Should this patient have a PET scan? According to HOMER, the prN1 ranges from 1.5% to 3.9% and a prN2|3 of 5.2% to 36.6%, depending on the PET N stage. The European Society of Thoracic Surgery (ESTS) suggests that proceeding to thoracotomy is reasonable, provided the probability of finding N2|3 disease at the time of surgery is less than 10%.³⁰ A PET scan would be useful in this patient, because a PET N0 result would lead to surgery (prN2|3 < 10% threshold), whereas a PET showing nodal uptake would change management to EBUS (prN2|3 > 10% threshold). Conversely, if a patient instead had CT N2 disease, the prN1 ranges from 4.6% to 6.0%, and the prN2|3 ranges from 12.7% to 69.8%, depending on the PET N stage. In this case, we see that regardless of the PET N stage, the lowest the prN2|3 will be is 12.7%, which is higher than the suggested ESTS 10% threshold.³⁰ Therefore, EBUS sampling in this case will be warranted no matter what, so proceeding directly to EBUS rather than waiting for a PET scan is warranted. In both patients, calculating the range of probabilities is useful.

The second decision that HOMER can inform is determining whether EBUS should be done.¹⁷ For

instance, consider two cases in which SABR is a treatment option. In the first case (A), a 60-year-old patient with a peripheral undifferentiated NSCLC, PET-CT N0, who is surgically fit but prefers SABR, is evaluated. HOMER predicts a 93% prN0 disease. In the second case (B), an 80-year-old patient with severe COPD who cannot tolerate lobectomy has a peripheral squamous cell carcinoma PET-CT N0. HOMER predicts a 98% prN0 disease. In both cases, finding N2 disease would lead to multimodal chemoradiation over SABR. However, in case A, finding N1 disease leads to surgery, whereas in case B it leads to definitive radiation therapy (alone or with chemotherapy).^{8,17} In case A, when weighing the risk of complications at approximately 1.15%³¹ vs the probability of occult nodal involvement at 7%, EBUS seems warranted because nodal involvement will change treatment from SABR to surgery with adjuvant chemotherapy or chemoradiation. Conversely, in case B, where there is only a 2% probability of finding malignant nodal disease vs a 1.15% risk of complications,³¹ proceeding directly to SABR seems reasonable.¹⁷ Although the absolute difference in probability of occult nodal metastasis between the two scenarios is small (2% vs 7%), the decision context is complex and involves consideration of the probability of EBUS being positive.

The third decision the models inform is whether confirmatory mediastinoscopy is warranted in patients that have a negative EBUS.¹⁰ Guidelines recommend that if EBUS is negative for malignancy in the N2|3 nodes but the suspicion of mediastinal nodal involvement remains high, mediastinoscopy be performed.⁸ But the guidelines do not identify which patients with a negative EBUS are high risk for nodal disease and which patients have a sufficiently low risk that proceeding directly to lobectomy is warranted. HAL can inform this decision. Because we know the sensitivity and specificity of EBUS, HAL can be used to approximate the pretest prN2|3 disease that can, in turn, be used to estimate the posterior probability of N2|3 disease given a negative EBUS (see [e-Appendix 1](#) for details). The posterior probability of N2|3 disease then informs the decision on whether a confirmatory mediastinoscopy is necessary; if it is less than the surgical decision threshold (eg, ESTS threshold of 10%), then proceeding directly to lobectomy is warranted, whereas if it is greater than the decision threshold probability, confirmatory mediastinoscopy is

warranted.^{10,30} HAL and HOMER do not dictate what the surgical decision threshold probability or what the next step in management is, but merely inform and improve the decision process.

HAL and HOMER also refine and challenge existing paradigms with large lesions (>3cm) that are PET-CT N0. The ACCP lung cancer guidelines recommend that for patients with a peripheral clinical stage IA tumor (PET-CT N0), invasive preoperative evaluation of the mediastinal node is not required (Grade 2B).¹ The ACCP guidelines remain silent on whether peripheral tumors > 3 cm that are PET-CT N0 should have invasive preoperative evaluation of the mediastinal nodes. However, indirectly they imply that it would be reasonable to do mediastinal staging in such lesions. Similarly, the NCCN guidelines do recommend that patients with tumors > 3 cm that are PET-CT N0 undergo invasive preoperative evaluation of the mediastinal nodes.⁸ However, HAL and HOMER suggest that the probability of malignant nodal disease in patients with PET-CT N0 disease is low enough that foregoing EBUS-TBNA would be reasonable even when the tumor is large. Indeed, in this study, among 198 patients with peripheral lesions measuring >3 cm who were PET-CT N0, only two (1.0%; 95% CI, 0.1%-3.6%; [e-Table 8](#)) had N2|3 disease by EBUS. Note that the upper bound of the 95% credible interval of the proportion of patients having N2|3 disease by EBUS is significantly less than the 10% surgical threshold suggested by the ESTS ($P < .001$, binomial exact test).³⁰ Therefore, although the guidelines indirectly suggest that patients with tumors measuring > 3 cm warrant EBUS, our data suggest that foregoing EBUS in select cases might be reasonable.

This study is the first multicenter prospective external and temporal validation of a clinical prediction model for mediastinal and hilar nodal involvement as determined by EBUS. Future studies will be needed to test the utility of the models and determine whether they impact care. Integration of HAL and HOMER into electronic decision aids may facilitate these endeavors. A webpage is now available that can be used to calculate nodal metastasis probabilities using HOMER,³² and prediction tables are in [e-Tables 9 and 10](#).

However, although HAL and HOMER have both been shown to have overall good performance, it is important to acknowledge their limitations, especially as applied to clinical practice. First, HAL and HOMER demonstrated

some calibration issue in one institution (The Royal Melbourne Hospital). Also, performance might vary significantly in other settings if the type of EBUS staging procedure were changed. In this study, all patients had systematic staging, with sampling of all lymph nodes measuring ≥ 5 mm by EBUS. If this were changed, HAL and HOMER might not perform as well. In addition, HAL and HOMER predict EBUS results, and EBUS has limitations in terms of its sensitivity,³³ which must be accounted for as previously described.^{10,17} Finally, HAL and HOMER are dependent on the cytopathologist interpreting the samples. If there is significant variability between centers in terms of specimen handling or cytopathologist interpretation, this will impact model performance.

Interpretation

In summary, we found that both HAL and HOMER performed well across multiple institutions in terms of their ability to predict mediastinal and hilar lymph node metastasis as identified by EBUS. The data provide external validation as well as temporal validation for the models. Discrimination and calibration were good, as assessed by observed vs predicted plots and Brier scores. The Hosmer-Lemeshow test suggested some degree of calibration error. The magnitude of the calibration error was small, such that the models are acceptable for clinical use.²⁷ Future studies will need to assess their utility and hopefully use these models to improve lung cancer care.

Acknowledgments

Author contributions: D. E. O. was the principal investigator for this study and was responsible for project conception, oversight, organization, data collection and auditing, statistical analysis, and manuscript writing. G. M.-Z. participated in data collection, statistical analysis, and manuscript writing. J. S., J. M., and L. L. were the primary biostatisticians and were responsible for data analysis and writing and editing. F. A. A., L. Y., D. S., D. R. L., T. D., D. K. D., L. M., J. J. F., S. M., C. A., J. T., A. B., A. M. R., D. K. H., M. D., A.-E. S. S., H. B., J. C., D. H. Y., A. C., L. F., H. B. G., D. F.-K., M. H. A., S. S., G. A. E., C. A. J., L. L., M. R., L. N., A. M., H. C., R. F. C., S. M., T. S., M. J. S., M. M., T. G., and L. G. D. participated in data abstraction, writing, and editing. All authors approved the final version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. D. E. O. and G. M.-Z. take full responsibility for the integrity of the work as a whole, from inception to published article.

Financial/nonfinancial disclosures: The authors have reported to *CHEST* the following: R. F. C. holds grants with Siemens and Olympus and is a consultant for Siemens, Olympus, and Verix. S. M. is an educational consultant for Johnson & Johnson, Boston Scientific, Olympus, Cook Inc, Medtronic, and Pinnacle Biologics. T. S. has received consulting and speaking fees from Veracyte, consulting fees from Astra-Zeneca, and is consultant for Medtronic. M. J. S. is a consultant for Intuitive Surgical, Gongwin Biopharm, and is a previous consultant for Auris Robotics. M. M. is consultant for Olympus America and is a previous consultant for Auris Robotics. None declared (G. M.-Z., F. A. A., L. Y., D. S., D. R. L., T. D., D. K. D., L. M., J. J. F., S. M., C. A., J. T., A. B., A. M. R., D. K. H., M. D., A.-E. S. S., H. B., J. C., L. G. B., D. H. Y., A. C., L. F., H. B. G., T.

G., D. F.-K., M. H. A., S. S., G. A. E., C. A. J., L. L., M. R., L. N., A. M., J. S., H. C., J. M., L. L., D. E. O.).

Other contributions: The authors thank Linda Conry, MA, for editorial assistance in the preparation of this manuscript.

Additional information: The e-Appendix, e-Figures, and e-Tables can be found in the Supplemental Materials section of the online article.

References

- Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer. In: *Diagnosis and Management of Lung Cancer*, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5 Suppl): e211S-e250S.
- Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer. In: *Diagnosis and Management of Lung Cancer*, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5 Suppl): e278S-e313S.
- Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. *N Engl J Med*. 2017;377(9): 849-861.
- Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer. In: *Diagnosis and Management of Lung Cancer*, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5 Suppl):e314S-e340S.
- Ost DE, Jim Yeung SC, Tanoue LT, Gould MK. Clinical and organizational factors in the initial evaluation of patients with lung cancer. In: *Diagnosis and Management of Lung Cancer*, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5 Suppl):e121S-e141S.
- Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer. In: *Diagnosis and Management of Lung Cancer*, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5 Suppl): e142S-e165S.
- Czarnecka-Kujawa K, Rochau U, Siebert U, et al. Cost-effectiveness of mediastinal lymph node staging in non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2017;153(6):1567-1578.
- National Comprehensive Cancer Network. Non-small cell lung cancer (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf; 2019. Accessed June 3, 2021.
- Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? *Diagnosis and Management of Lung Cancer*, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5 Suppl):e93S-e120S.
- O'Connell OJ, Almeida FA, Simoff MJ, et al. A prediction model to help with the assessment of adenopathy in lung cancer: HAL. *Am J Respir Crit Care Med*. 2017;195(12):1651-1660.
- Shafazand S, Gould MK. A clinical prediction rule to estimate the probability of mediastinal metastasis in patients with non-small cell lung cancer. *J Thorac Oncol*. 2006;1(9):953-959.
- Zhang Y, Sun Y, Xiang J, Zhang Y, Hu H, Chen H. A prediction model for N2 disease in T1 non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2012;144(6): 1360-1364.
- Chen K, Yang F, Jiang G, Li J, Wang J. Development and validation of a clinical prediction model for N2 lymph node metastasis in non-small cell lung cancer. *Ann Thorac Surg*. 2013;96(5):1761-1768.

14. Koike T, Koike T, Yamato Y, Yoshiya K, Toyabe S. Predictive risk factors for mediastinal lymph node metastasis in clinical stage IA non-small-cell lung cancer patients. *J Thorac Oncol*. 2012;7(8):1246-1251.
15. Farjah F, Lou F, Sima C, Rusch VW, Rizk NP. A prediction model for pathologic N2 disease in lung cancer patients with a negative mediastinum by positron emission tomography. *J Thorac Oncol*. 2013;8(9):1170-1180.
16. Cho S, Song IH, Yang HC, Kim K, Jheon S. Predictive factors for node metastasis in patients with clinical stage I non-small cell lung cancer. *Ann Thorac Surg*. 2013;96(1):239-245.
17. Martinez-Zayas G, Almeida FA, Simoff MJ, et al. A prediction model to help with oncologic mediastinal evaluation for radiation: HOMER. *Am J Respir Crit Care Med*. 2020;201(2):212-223.
18. Casal RF, Sepesi B, Sagar AS, et al. Centrally located lung cancer and risk of occult nodal disease: an objective evaluation of multiple definitions of tumour centrality with dedicated imaging software. *Eur Respir J*. 2019;53(5):1802220.
19. Casal RF, Vial MR, Miller R, et al. What exactly is a centrally located lung tumor? results of an online survey. *Ann Am Thorac Soc*. 2017;14(1):118-123.
20. Dettterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. *Chest*. 2017;151(1):193-203.
21. Kinsey CM, Arenberg DA. Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging. *Am J Respir Crit Care Med*. 2014;189(6):640-649.
22. Ost DE, Ernst A, Lei X, et al. Diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration: results of the AQUIRE Bronchoscopy Registry. *Chest*. 2011;140(6):1557-1566.
23. Ost DE, Ernst A, Lei X, et al. Diagnostic yield and complications of bronchoscopy for peripheral lung lesions. results of the AQUIRE registry. *Am J Respir Crit Care Med*. 2016;193(1):68-77.
24. Steyerberg E. *Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating*. New York, NY: Springer; 2009.
25. Schultz EM, Sanders GD, Trotter PR, et al. Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. *Thorax*. 2008;63(4):335-341.
26. O'Connell OJ, Lazarus RST, Grosu HB, et al. Clinical predictors of hilar N3 disease in non-small cell lung cancer staging by EBUS. *American Thoracic Society (A5361)*. 2015.
27. Kramer A, Zimmerman J. Assessing the calibration of mortality benchmarks in critical care. *Crit Care Med*. 2007;35:2052-2056.
28. Porter ME. What is value in health care? *N Engl J Med*. 2010;363(26):2477-2481.
29. Ost DE, Niu J, Zhao H, Grosu HB, Giordano SH. Quality gaps and comparative effectiveness in lung cancer staging and diagnosis. *Chest*. 2020;157(5):1322-1345.
30. De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. *Eur J Cardiothorac Surg*. 2014;45(5):787-798.
31. Eapen GA, Shah AM, Lei X, et al. Complications, consequences, and practice patterns of endobronchial ultrasound-guided transbronchial needle aspiration: results of the AQUIRE registry. *Chest*. 2013;143(4):1044-1053.
32. Ost D, Martinez-Zayas G, Ma J, Norris C. Predicting mediastinal lymph node involvement in patients with non-small cell lung cancer. <https://biostatistics.mdanderson.org/shinyapps/HOMER/>. Accessed June 3, 2021.
33. Leong TL, Loveland PM, Gorelik A, Irving L, Steinfurt DP. Preoperative staging by EBUS in cN0/N1 lung cancer: systematic review and meta-analysis. *J Bronchol Interv Pulmonol*. 2019;26(3):155-165.